The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV.
Ifedioranma AnikpoAfiba Manza-A AgoviMatthew J CvitanovichFrank LonerganMarc JohnsonRohit P OjhaPublished in: HIV medicine (2021)
The D:A:D model was miscalibrated for CVD risk among PLWH engaged in HIV care at an urban safety-net HIV clinic, which may be related to differences in case-mix and baseline CVD risk. Nevertheless, the HIV D:A:D model may be useful for decisions about CVD intervention for high-risk patients.
Keyphrases
- antiretroviral therapy
- cardiovascular events
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- end stage renal disease
- men who have sex with men
- coronary artery disease
- randomized controlled trial
- cardiovascular disease
- ejection fraction
- primary care
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- electronic health record